Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FS102 in HER2 Positive Solid Tumors
NCT02286219Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2014
- Primary completion
- Jun 2017
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of FS102 in HER2-positive solid tumor, sponsored by Bristol Myers Squibb. Primary endpoint: Adverse events as assessed by NCI Common Toxicity Criteria for Adverse Events CTCAE v3.0 at 1 year. Started Nov 2014; status: completed.
02
Drugs
FS102
03
Conditions
HER2-positive solid tumor
Beyond the preview
Go deeper on NCT02286219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02286219.